CAJ | 학술논문

热休克蛋白（Hsp90）是一类高度保守的蛋白质。近年的研究表明，Hsp90与肿瘤的发生及转移有高度的相关性，因此一些小分子Hsp90抑制剂被发现具有广泛的抗肿瘤增殖及转移的作用。 NVP－AUY922是其中一种具有吡咯骨架的人工合成制剂，由于它具有毒副作用小和结构稳定等优点，被人们广泛考虑作为新一类的抗肿瘤药物使用。本篇综述主要就AUY922单药及与其他药物联合使用治疗肿瘤的研究进展做一综述。
열휴극단백（Hsp90）시일류고도보수적단백질。근년적연구표명，Hsp90여종류적발생급전이유고도적상관성，인차일사소분자Hsp90억제제피발현구유엄범적항종류증식급전이적작용。 NVP－AUY922시기중일충구유필각골가적인공합성제제，유우타구유독부작용소화결구은정등우점，피인문엄범고필작위신일류적항종류약물사용。본편종술주요취AUY922단약급여기타약물연합사용치료종류적연구진전주일종술。
Heat shock protein 90(Hsp90)is a highly conserved protein which have been proved to play an important role in the development and progression of malignant transformation .As one of small molecule inhibi-tors that has been detected to have potent antitumor activity in a wide range of malignancies ,NVP-AUY922 is a pyrazole scaffold drug with many advantages such as low toxicity and stable structure .As a result of this,NVP-AUY922 is extensively considered as a new promising kind of anti -tumor drug .This review intends to update the reader on advances made over the past four years in the clinical development of NVP -AUY922 in advanced cancers.